ArticleGeneral thoracic and cardiovascular surgery2026
Neoadjuvant immunotherapy and the stepwise risk of postoperative atrial fibrillation: a propensity score-matched analysis isolating surgical and biological triggers.
Article in General thoracic and cardiovascular surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNeoadjuvant immunotherapy has transformed the management of resectable non-squamous cell lung cancer (NSCLC). However, the specific arrhythmogenic potential of immune checkpoint inhibitors (ICIs) in the postoperative setting remains poorly characterized. This study aimed to isolate the independent impact of neoadjuvant immunotherapy on postoperative atrial fibrillation (POAF) and quantify its clinical consequences.
methodsWe analyzed 1,610 patients undergoing anatomic lung resection for Stage II-III NSCLC between 2020 and 2025. To decouple the ICI effect from chemotherapy and eliminate selection bias, a 1:1:1 propensity score-matched (PSM) analysis based on baseline clinical and demographic characteristics was performed to create three balanced cohorts (n = 400 each, Total N = 1,200): (1) upfront surgery (Control), (2) isolated neoadjuvant chemotherapy (nCT), and (3) neoadjuvant chemo-immunotherapy (nCIT).
resultsFollowing PSM, all baseline cardiac risk factors achieved statistical parity (p > 0.05). A significant stepwise escalation in POAF incidence was observed: 11.5% in the Control group, 15.1% in the nCT group, and 23.5% in the nCIT group (p < 0.001). Multivariable analysis isolated the specific immunotherapy effect, revealing that the addition of ICIs independently increased POAF odds by 2.28-fold (95% CI: 1.45-3.65, p < 0.001) compared to chemotherapy alone. Clinically, POAF development in the immunotherapy cohort resulted in a significant extension of the median hospital stay (10.4 vs. 5.6 days, p < 0.001) and ICU stay (3.2 vs. 1.4 days, p < 0.001). This specific ICI effect appeared to correlate with an enhanced systemic inflammatory response and increased surgical complexity observed during hilar dissection.
conclusionModern neoadjuvant protocols suggest that the immunotherapy component contributes to a higher likelihood of POAF. Consequently, integrating careful perioperative cardiac monitoring and tailored management approaches for these patients could be beneficial in improving clinical outcomes and optimizing the use of hospital resources.
Indexed as
Identifiers
42217119What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.